NASDAQ:MRUS - Merus Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $29.40
  • Forecasted Upside: 31.72 %
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$22.32
▲ +0.57 (2.62%)

This chart shows the closing price for MRUS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Merus Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MRUS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MRUS

Analyst Price Target is $29.40
▲ +31.72% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Merus in the last 3 months. The average price target is $29.40, with a high forecast of $33.00 and a low forecast of $21.00. The average price target represents a 31.72% upside from the last price of $22.32.

This chart shows the closing price for MRUS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 6 polled investment analysts is to buy stock in Merus. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/31/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/30/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/28/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/26/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/25/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/25/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/24/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/23/2021

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/11/2021William BlairReiterated RatingBuyLow
6/7/2021CitigroupUpgradeNeutral ➝ BuyHigh
6/7/2021Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellUpgradeNeutral ➝ Buy$24.00 ➝ $31.00High
5/9/2021SVB LeerinkReiterated RatingBuy$33.00High
4/8/2021William BlairInitiated CoverageOutperformMedium
3/17/2021Royal Bank of CanadaBoost Price TargetSector Perform$15.00 ➝ $21.00Low
3/17/2021HC WainwrightBoost Price TargetBuy$23.00 ➝ $30.00Medium
3/16/2021SVB LeerinkInitiated CoverageOutperform$33.00High
1/19/2021Roth CapitalBoost Price Target$19.00 ➝ $32.00High
8/7/2020HC WainwrightReiterated RatingBuy$23.00High
7/14/2020HC WainwrightReiterated RatingBuy$23.00High
6/26/2020HC WainwrightInitiated CoverageBuy$23.00High
5/27/2020Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$21.00 ➝ $16.00High
5/18/2020GuggenheimLower Price TargetBuy$26.00 ➝ $23.00High
5/13/2020Royal Bank of CanadaReiterated RatingBuy$21.00Low
11/20/2019GuggenheimInitiated CoverageBuy$25.00Medium
6/28/2019Roth CapitalInitiated CoverageBuy ➝ Buy$20.00High
4/12/2019GuggenheimInitiated CoverageBuy$25.00High
4/5/2019WedbushLower Price TargetOutperform ➝ Outperform$34.00 ➝ $25.00Low
4/3/2019Royal Bank of CanadaUpgradeSector Perform ➝ Outperform$18.00 ➝ $23.00High
3/27/2019Berenberg BankInitiated CoverageBuy ➝ Buy$35.00High
3/21/2019CitigroupLower Price TargetNeutral ➝ Neutral$18.00 ➝ $16.00Medium
3/15/2019CitigroupLower Price TargetNeutral ➝ Neutral$18.00 ➝ $16.00Low
7/27/2018WedbushReiterated RatingOutperform ➝ Outperform$26.00 ➝ $34.00Low
4/30/2018WedbushReiterated RatingOutperform$26.00 ➝ $32.00Low
1/12/2018WedbushReiterated RatingOutperform$32.00Medium
1/2/2018Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$28.00High
10/26/2017Jefferies Financial GroupReiterated RatingBuy$30.00N/A
10/18/2017Royal Bank of CanadaReiterated RatingBuy$28.00N/A
9/14/2017Royal Bank of CanadaInitiated CoverageOutperform ➝ Outperform$28.00High
7/14/2017Jefferies Financial GroupReiterated RatingBuy$31.00Low
6/6/2017WedbushReiterated RatingOutperform$32.00High
5/4/2017Jefferies Financial GroupLower Price TargetBuy$33.00 ➝ $31.00Medium
4/26/2017Jefferies Financial GroupReiterated RatingBuy$33.00Low
3/21/2017CitigroupDowngradeBuy ➝ Neutral$31.00High
2/17/2017Jefferies Financial GroupBoost Price TargetBuy$33.00N/A
12/29/2016CitigroupUpgradeBuyN/A
12/25/2016Jefferies Financial GroupSet Price TargetBuy$29.00N/A
12/23/2016WedbushReiterated RatingOutperform$16.00 ➝ $32.00N/A
12/22/2016CitigroupUpgradeNeutral ➝ Buy$19.00 ➝ $26.00N/A
11/8/2016Jefferies Financial GroupReiterated RatingBuy$21.00N/A
11/7/2016CitigroupDowngradeBuy ➝ Neutral$14.00 ➝ $19.00N/A
7/13/2016Jefferies Financial GroupReiterated RatingBuy$19.00N/A
7/12/2016WedbushReiterated RatingOutperform$14.00N/A
(Data available from 6/23/2016 forward)
Merus logo
Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trial for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 for the pancreatic and lung cancer, and other solid tumors. The company is also developing MCLA-117 that is in phase I clinical trial for the treatment of patients with acute myeloid leukemia; MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat autoimmune disease. In addition, its research and development stage bispecific antibody candidates include MCLA-129, which is being developed in collaboration with Betta Pharmaceuticals Co. Ltd; MCLA-145, which is being developed in collaboration with Incyte Corporation; and clinical programs to explore potential combination therapies or indication. Merus N.V. has collaborations and license agreement with Loxo Oncology at Lilly to discover and research novel T-cell re-directing bispecific antibodies. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.
Read More

Today's Range

Now: $22.32
Low: $21.52
High: $22.50

50 Day Range

MA: $22.01
Low: $20.00
High: $25.48

52 Week Range

Now: $22.32
Low: $10.18
High: $31.27

Volume

99,980 shs

Average Volume

190,578 shs

Market Capitalization

$855.97 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.63

Frequently Asked Questions

What sell-side analysts currently cover shares of Merus?

The following Wall Street analysts have issued research reports on Merus in the last twelve months: Citigroup Inc., Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell, HC Wainwright, Roth Capital, Royal Bank of Canada, SVB Leerink LLC, William Blair, and Zacks Investment Research.
View the latest analyst ratings for MRUS.

What is the current price target for Merus?

5 Wall Street analysts have set twelve-month price targets for Merus in the last year. Their average twelve-month price target is $29.40, suggesting a possible upside of 31.7%. SVB Leerink LLC has the highest price target set, predicting MRUS will reach $33.00 in the next twelve months. Royal Bank of Canada has the lowest price target set, forecasting a price of $21.00 for Merus in the next year.
View the latest price targets for MRUS.

What is the current consensus analyst rating for Merus?

Merus currently has 1 hold rating and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe MRUS will outperform the market and that investors should add to their positions of Merus.
View the latest ratings for MRUS.

What other companies compete with Merus?

How do I contact Merus' investor relations team?

Merus' physical mailing address is YALELAAN 62, UTRECHT P7, 3584 CM. The biotechnology company's listed phone number is 31-0-30-253-8800 and its investor relations email address is [email protected] The official website for Merus is www.merus.nl.